NMIBC Clinical Trials

5 recruitingLast updated: May 4, 2026

NMIBC Trials at a Glance

13 actively recruiting trials for nmibc are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Beijing, Nashville, and Myrtle Beach. Lead sponsors running nmibc studies include ImmunityBio, Inc., Jiangsu Simcere Pharmaceutical Co., Ltd., and Changhai Hospital.

Browse nmibc trials by phase

Treatments under study

About NMIBC Clinical Trials

Looking for clinical trials for NMIBC? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NMIBC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NMIBC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled35 locationsNCT06995677
Recruiting

Bladder EpiCheck Product Development Study

Suspicion of Bladder CancerNMIBC Surveillance
Nucleix Ltd.1,000 enrolled2 locationsNCT07514143
Recruiting
Phase 1Phase 2

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

NMIBC
ImmunityBio, Inc.40 enrolled9 locationsNCT06800963
Recruiting
Not Applicable

Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study

Muscle-Invasive Bladder CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)
University of Aarhus30 enrolled1 locationNCT07339761
Recruiting
Phase 2

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc.90 enrolled16 locationsNCT03945162
Recruiting
Phase 1

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)
Ractigen Therapeutics.72 enrolled3 locationsNCT06351904
Recruiting

A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

NMIBCMIBCUTUC
Peking University First Hospital300 enrolled1 locationNCT06991868
Recruiting
Not Applicable

A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer

Bladder CancerNMIBC
The First Affiliated Hospital with Nanjing Medical University60 enrolled1 locationNCT06735287
Recruiting
Not Applicable

Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

NMIBC
Changhai Hospital72 enrolled1 locationNCT06889623
Recruiting
Phase 3

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang180 enrolled3 locationsNCT06696794
Recruiting
Phase 1Phase 2

A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd.150 enrolled1 locationNCT05410730
Recruiting
Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jiangsu Simcere Pharmaceutical Co., Ltd.152 enrolled14 locationsNCT06186414
Recruiting
Phase 2

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

NMIBC
RemeGen Co., Ltd.85 enrolled1 locationNCT05943379